Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 5/20 | 0.53 |
| ▸ | TACR1 | P25103 | 3/20 | 0.48 |
| ▸ | NOS2 | P35228 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MME | P08473 | 1/20 | 0.43 |
| ▸ | ACE | P12821 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.42 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.42 |
| ▸ | FPR2 | P25090 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2859969 | 1.00 | ACACB (0.53) | ACACBTACR1NOS2LMNAMME | |
| SCHEMBL3048692 | 0.87 | TACR1 (0.50) | ACACBTACR1MMEACE | |
| SCHEMBL3048691 | 0.87 | TACR1 (0.50) | ACACBTACR1MMEACE | |
| SCHEMBL2856542 | 0.87 | NOS2 (0.58) | ACACBTACR1NOS2ALDH1A1 | |
| SCHEMBL2856548 | 0.87 | NOS2 (0.58) | ACACBTACR1NOS2ALDH1A1 | |
| SCHEMBL29469535 | 0.87 | NOS2 (0.58) | ACACBTACR1NOS2ALDH1A1 | |
| SCHEMBL5887606 | 0.86 | TACR1 (0.46) | ACACBTACR1LMNASRCZAP70 | |
| SCHEMBL5887604 | 0.86 | TACR1 (0.46) | ACACBTACR1LMNASRCZAP70 | |
| SCHEMBL5887794 | 0.86 | ACACB (0.53) | ACACBTACR1LMNASRCZAP70 | |
| SCHEMBL5887793 | 0.86 | ACACB (0.53) | ACACBTACR1LMNASRCZAP70 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1346971-B1 | Production method for biarylalanine | SUMITOMO CHEMICAL CO (JP) | 2010-01-20 | — | — | EP | disclosed |
| US-7091373-B2 | Production method for biarylalanine | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-08-15 | — | — | US | disclosed |
| US-20040024229-A1 | Production method for biarylalanine | SUMITOMO CHEMICAL COMPANY, LIMITED | 2004-02-05 | — | — | US | disclosed |
| EP-1346971-A1 | Production method for biarylalanine | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024229-A1 | Production method for biarylalanine | BCAT2, BCAT1, PAH | ACACB 2960/4885TACR1 2442/4885NOS2 421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.